Skin Renewing Serumascorbic acid

According to the FDA label: Ascorbic acid injection is indicated for the short term (up to 1 week) treatment of scurvy in adult and pediatric patients, age 5 months and older, for whom oral administration is not possible, insufficient or contraindicated. Limitations of Use Ascorbic acid injection is not indicated for the treatment of vitamin C deficiency that is not associated with signs and symptoms of scurvy.

22,822 adverse event reports submitted to the FDA (1999–2026)

This data reflects voluntary reports submitted to the FDA's Adverse Event Monitoring System (AEMS), formerly the FDA Adverse Event Reporting System (FAERS). A report does not mean the medication caused the event. Data may be incomplete or contain errors. Learn more about AEMS. New to this data? Read our guide on how to interpret FDA adverse event reports →
New to FDA adverse event data? Here's how to read these reports →

Top Reported Adverse Events

The most frequently reported events in association with Skin Renewing Serum in the FAERS database. These are events reported by patients taking this medication, not necessarily caused by it. A single report may include multiple events.

Show these terms with plain-language definitions

Tap any term below for a plain-language definition.

Browse the full glossary →

Ranked by frequency of reports, not severity. The most-reported event is not necessarily the most dangerous or the most common in patients taking this drug.

Who Is Reporting

Demographics of patients in FAERS reports that included this information. Not all reports include patient demographics.

By Sex

View reporter sex data as a table
Skin Renewing Serum adverse event reports by reporter sex
SexReports
Female13,579
Male7,966
Unknown15

By Age Group

View age group data as a table
Skin Renewing Serum adverse event reports by reporter age group
Age groupReports
0-17355
18-34963
35-492,348
50-644,113
65-743,551
75+3,542

This shows who filed reports, reflecting who takes this drug and who tends to report, not who is at greatest risk.

Reported Outcomes

Outcomes recorded in FAERS reports that included Skin Renewing Serum. A single report may involve multiple reactions, each with a different outcome. These categories are defined by FDA reporting guidelines, not by PillSignal.

View outcome data as a table
Skin Renewing Serum adverse event reports by reported outcome
OutcomeReports
Other Serious10,557
Hospitalization9,135
Non-Serious6,462
Death2,571
Life-Threatening1,685
Disability1,524

Serious outcomes are far more likely to be reported than mild ones, so this overstates how often outcomes are serious. A recorded death does not mean the drug caused it.

Number of FAERS reports received per quarter for Skin Renewing Serum. Changes in volume may reflect shifts in prescribing rates, media attention, or reporting behavior, not changes in the medication's safety profile.

View report trend as a table
Skin Renewing Serum adverse event reports by year
YearReports
19991
2004369
2005809
2006873
2007888
20081,124
20091,295
20101,094
20111,807
20121,840
2013427
2014485
2015493
2016660
2017793
20181,049
20191,029
20201,325
20211,276
20221,322
20231,221
20241,304
20251,081
2026 (partial)257

The steep increase around 2004 reflects the FDA's move to electronic submission, not a change in this drug's safety. Trends track reporting volume, not risk.

Medications commonly reported with Skin Renewing Serum

In FDA adverse event reports that mention Skin Renewing Serum, these medications appeared most often in the same report.

This reflects co-occurrence in submitted reports, not evidence of drug interaction or combined risk. People often report several medications taken for the same condition or for unrelated reasons. Talk to a doctor or pharmacist about your specific medications.

Other medications with similar adverse event profiles in FDA FAERS reports.

Data Source

This data is sourced from the FDA's Adverse Event Monitoring System (AEMS), formerly FAERS, via the OpenFDA API. PillSignal is not affiliated with the FDA.

View this data on the FDA website →

Data last updated: June 2026